Stayble Therapeutics AB (STABL) — Cash Flow Reinvestment Rate
Latest as of December 2019:
0.00x
Stayble Therapeutics AB (STABL) has a Cash Flow Reinvestment Rate of 0.00x as of December 2019, reinvesting Skr0.00 (capex Skr0.00 ) from operating cash flow of Skr3.76 Million. See STABL equity financing ratio to measure how much of total assets are equity-financed.
Reinvestment Rate
0.00x
(Capex + Investments) / Operating CF
Total Reinvested
Skr0.00
Capex + Investments
Operating Cash Flow
Skr3.76 Million
SEK
Capital Expenditures
Skr0.00
SEK
Stayble Therapeutics AB Cash Flow Reinvestment Rate (2019–2019)
Historical reinvestment intensity for Stayble Therapeutics AB across 1 annual periods. Also explore STABL total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Stayble Therapeutics AB (2019–2019)
Year-by-year capital reinvestment analysis for Stayble Therapeutics AB. For live market cap and broader valuation context, see how much is Stayble Therapeutics AB worth.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2019 | 0.00x | Skr1.00K | Skr289.39K | Skr0.00 | — |
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow